8-K filing — Monte Rosa Therapeutics, Inc. (GLUE)
Filed: 2026-09-08 AccNo: 0001193125-26-384360 Size: 246 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Monte Rosa Therapeutics Announces $50M Milestone Payment From Novartis On First Patient Visit In Phase 2 Study Of MRT-6160 In Sjögren's Disease
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target
Guggenheim analyst Michael Schmidt reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $28 price target.
Monte Rosa Therapeutics Says First Patient Dosed In Modefire-1, Phase 2 Study Evaluating MRT-2359 In Combination With Apalutamide In Patients With mCRPC With AR Mutations